Antibody identification is needed to determine the risk of hemolytic disease of the newborn.
The ANA Screen detects the presence of clinically relevant circulating autoantibodies in serum or plasma.
Antinuclear antibodies are present in systemic lupus erythematosus, Sjogren’s Syndrome, scleroderma, mixed connective tissue disease, drug induced lupus, and rheumatoid arthritis.
Bilirubin levels are useful in the diagnosis of metabolic, liver, hematologic, and hemolytic disorders.